EBS News and Press, Emergent Biosolutions Inc. From 01/05/23

Emergent BioSolutions ( NYSE: EBS ) on Thursday said it had been awarded a contract valued up to ~$380M to supply skin decontamination lotion kits for use by all branches of the U.S. military. EBS shares gained 11.8% to $13.80 after hours. EBS' Canadian unit will serve as the ...

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL ® (Reactive Skin Decontaminati...

Summary We realized an extensive loss on our EBS position in FY21, following the string of controversies it was caught up in. After revisiting the stock and deep examination of the investment case at hand, there's a lack of equity premia to harvest at present. Not to say things can'...

Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA. NARCAN ® (naloxone HCI) Nasal Spray 4 mg, the first intranasal form of naloxone approved by the FDA in 2015, i...

Emergent BioSolutions (EBS) said it received a research award from the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate its single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Em...

GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya...

Emergent BioSolutions ( NYSE: EBS ) is trading ~30% lower after the company missed Q3 estimates and lowered its full-year guidance, hurt by lower sales of Nasal naloxone products, ACAM2000. For Q3 , revenues from nasal naloxone products decreased 34% ...

Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q3 2022 Earnings Call Nov 08, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Conference Call November 08, 2022 05:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer ...

Emergent Biosolutions press release ( NYSE: EBS ): Q3 Non-GAAP EPS of -$1.27 misses by $1.14 . Revenue of $240M (-27.1% Y/Y) misses by $26.35M . Guidance 2022: Total Revenues $1.05B to $1.1B. Prior total revenue outlook of $1.15B to $1.25B vs. con...